Scienture Q3 Revenue Hits $1.25M, Up 265% Sequentially on REZENOPY Launch
SCNX is trading near its 52-week low of $2.24 (8.7% above the low) on light trading volume (0.2× avg).
Summary
Scienture reported Q3 2026 revenue of $1.25 million (up ~265% sequentially) and $1.02 million of gross profit, driven by the REZENOPY launch, but still posted a $6.0 million net loss with $7.8 million of cash on hand.
Key Events · Earnings and Guidance · SCNX
-
Q3 Revenue Jumps 265% Sequentially
Revenue rose to $1.25 million from $343,639 in Q2 2026 and $590,050 in Q3 2025, exceeding the company's own preliminary estimate of approximately $1.22 million.
-
REZENOPY Launch Drives Product Sales
Initial wholesale shipments of REZENOPY generated approximately $925,000 of net product revenue after its August 2026 launch; Arbli contributed approximately $330,000 in Q3.
-
Gross Margin 81.3%, Net Loss $6.0M
Q3 gross profit was $1.02 million at an 81.3% margin, but operating loss was approximately $5.7 million and net loss approximately $6.0 million, versus a $3.6 million net loss in Q3 2025 that included a $2.4 million non-cash derivative gain.
-
Cash of $7.8M Against 2027 Profit Target
Cash, cash equivalents and restricted cash totaled approximately $7.8 million at September 30, 2026; management says it is poised to reach $6M breakeven operating income and be profitable in 2027.
Analysis · SCNX · Life Sciences
Scienture's second commercial product is now producing real revenue: REZENOPY's August launch contributed roughly $925,000 of the $1.25 million in Q3 net product sales, and gross profit reached $1.02 million at an 81.3% margin. The catch is that operating costs are still running far ahead of gross profit — a $5.7 million Q3 operating loss and a $6.0 million net loss — so the company is still burning cash even as sales ramp. Management's claim that it can reach $6 million breakeven operating income and be profitable in 2027 is the number that matters; the $7.8 million of cash and restricted cash on hand is the runway against which that promise gets tested.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNX was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $2.24 to $18.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.